Research programme: amyotrophic lateral sclerosis therapeutics - Iron Horse Therapeutics

Drug Profile

Research programme: amyotrophic lateral sclerosis therapeutics - Iron Horse Therapeutics

Alternative Names: EPH receptor 4 inhibitors - Iron Horse Therapeutics; EphA4 inhibitors - Iron Horse Therapeutics; Ephrin type A receptor 4 inhibitors - Iron Horse Therapeutics

Latest Information Update: 19 Nov 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sanford-Burnham Medical Research Institute
  • Developer Iron Horse Therapeutics; Sanford Burnham Prebys Medical Discovery Institute
  • Class Small molecules
  • Mechanism of Action Eph family receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Amyotrophic lateral sclerosis

Most Recent Events

  • 09 Nov 2015 Preclinical trials in Amyotrophic lateral sclerosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top